Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths

108
12
Favorite

Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths

Bloomberg2022-04-06

Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

108

Report

Comment（12）

Xian789
·2022-04-06
Hope ended covid 19, going to normal situation soon
Reply
1
Report
blakonen
·2022-04-06
Yeah!
Reply
1
Report
SSVC
·2022-04-06
K
Reply
1
Report
Bull1973
·2022-04-06
Ok
Reply
2
Report
Road1Warrior
·2022-04-06
all i can tell here is that if there is a drug that is working in China then China won't lock down the whole city now
Reply
1
Report
Ck38
·2022-04-06
Like pls
Reply
2
Report
SvdB
·2022-04-06
Ok
Reply
1
Report
kevinlaisq
·2022-04-06
Pls like
Reply
1
Report
TaiJin
·2022-04-06
[Miser]
Reply
2
Report
Tinycub22
·2022-04-06
We shall see
Reply
2
Report
cbl
·2022-04-06
Hmm...
Reply
1
Report
aliciatng
·2022-04-06
Okay
Reply
5
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1178698720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-04-06 11:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178698720","market":"hk","top_or_hot":-1,"title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","media":"Bloomberg","content":"<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","article_id":"1178698720","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","pubTimestamp":1649216042,"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"09939":"开拓药业-B"},"translate_title":"中国制药公司金托尔（Kintor）表示，其药物减少了Covid死亡，股价飙升229%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09939":0.9},"content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9012075832,"gmtCreate":1649258329075,"gmtModify":1676534479868,"author":{"id":"4110928021767342","authorId":"4110928021767342","name":"Xian789","avatar":"https://community-static.tradeup.com/news/4ca7c600d474baab31a0389feb9440dd","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4110928021767342","idStr":"4110928021767342"},"htmlText":"Hope ended covid 19, going to normal situation soon","listText":"Hope ended covid 19, going to normal situation soon","text":"Hope ended covid 19, going to normal situation soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9012075832","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016478581,"gmtCreate":1649229239184,"gmtModify":1676534474148,"author":{"id":"3577948524439329","authorId":"3577948524439329","name":"blakonen","avatar":"https://static.tigerbbs.com/a78176b4839a262d0a9aeb2b9b2dc8d0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3577948524439329","idStr":"3577948524439329"},"htmlText":"Yeah!&nbsp;","listText":"Yeah!&nbsp;","text":"Yeah!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016478581","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016444022,"gmtCreate":1649227956007,"gmtModify":1676534474015,"author":{"id":"3574906731000207","authorId":"3574906731000207","name":"SSVC","avatar":"https://static.tigerbbs.com/545a5ea462ff4ac7cc100bd3d8d97f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3574906731000207","idStr":"3574906731000207"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016444022","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016445704,"gmtCreate":1649227952009,"gmtModify":1676534474008,"author":{"id":"3584680402793671","authorId":"3584680402793671","name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3584680402793671","idStr":"3584680402793671"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016445704","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016449342,"gmtCreate":1649226036291,"gmtModify":1676534473756,"author":{"id":"4098084219326670","authorId":"4098084219326670","name":"Road1Warrior","avatar":"https://community-static.tradeup.com/news/444bc0aeceab5292f15cd24cd37ab6c3","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"4098084219326670","idStr":"4098084219326670"},"htmlText":"all i can tell here is that if there is a drug that is working in China then China won't lock down the whole city now","listText":"all i can tell here is that if there is a drug that is working in China then China won't lock down the whole city now","text":"all i can tell here is that if there is a drug that is working in China then China won't lock down the whole city now","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016449342","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016428718,"gmtCreate":1649222688899,"gmtModify":1676534473385,"author":{"id":"3583102255464470","authorId":"3583102255464470","name":"Ck38","avatar":"https://static.tigerbbs.com/9b8be8ba545142480a0d1d5dc625e918","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3583102255464470","idStr":"3583102255464470"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016428718","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016487402,"gmtCreate":1649219905650,"gmtModify":1676534472946,"author":{"id":"3581903617103899","authorId":"3581903617103899","name":"SvdB","avatar":"https://static.tigerbbs.com/5122e985be0048597462b4591a72fb46","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581903617103899","idStr":"3581903617103899"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016487402","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016487151,"gmtCreate":1649219853726,"gmtModify":1676534472935,"author":{"id":"3572874548548490","authorId":"3572874548548490","name":"kevinlaisq","avatar":"https://static.tigerbbs.com/329de1199f764a89b7cadf50308e183d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3572874548548490","idStr":"3572874548548490"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016487151","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016412674,"gmtCreate":1649217821930,"gmtModify":1676534472671,"author":{"id":"3585363622677550","authorId":"3585363622677550","name":"TaiJin","avatar":"https://static.tigerbbs.com/24d2d840485600ee9789f516e956a70f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3585363622677550","idStr":"3585363622677550"},"htmlText":"[Miser]&nbsp;","listText":"[Miser]&nbsp;","text":"[Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016412674","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016413213,"gmtCreate":1649217159092,"gmtModify":1676534472572,"author":{"id":"4100607323115300","authorId":"4100607323115300","name":"Tinycub22","avatar":"https://static.tigerbbs.com/21cc125417073d9b3974e7b3f3303ef5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4100607323115300","idStr":"4100607323115300"},"htmlText":"We shall see","listText":"We shall see","text":"We shall see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016413213","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016413305,"gmtCreate":1649217094436,"gmtModify":1676534472564,"author":{"id":"3581735992939068","authorId":"3581735992939068","name":"cbl","avatar":"https://static.tigerbbs.com/45ebece1d4598598e1107d18b7e0fbb5","vip":1,"crmLevel":5,"crmLevelSwitch":0,"authorIdStr":"3581735992939068","idStr":"3581735992939068"},"htmlText":"Hmm...","listText":"Hmm...","text":"Hmm...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016413305","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9016437997,"gmtCreate":1649216506745,"gmtModify":1676534472475,"author":{"id":"3572214398550610","authorId":"3572214398550610","name":"aliciatng","avatar":"https://static.tigerbbs.com/c4b23ee891a1061c7907495a9c7da890","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3572214398550610","idStr":"3572214398550610"},"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9016437997","repostId":1178698720,"repostType":4,"repost":{"id":"1178698720","pubTimestamp":1649216042,"share":"https://ttm.financial/m/news/1178698720?lang=&edition=fundamental","pubTime":"2022-04-06 11:34","market":"hk","language":"en","title":"Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths","url":"https://stock-news.laohu8.com/highlight/detail?id=1178698720","media":"Bloomberg","summary":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly e","content":"<html><head></head><body><p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.</p><p>Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.</p><p>The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.</p><p>Read more: China Drugmaker’s 580% Surge Has Analysts Wanting More</p><p>If results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck &amp; Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.</p><p>Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.</p><p>The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese Pharma Firm Kintor Surges 229% After Saying Its Drug Reduces Covid Deaths\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-04-06 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect...</p>\n\n<a href=\"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09939":"开拓药业-B"},"source_url":"https://finance.yahoo.com/news/chinese-pharma-firm-kintor-surges-032742103.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178698720","content_text":"Chinese drug maker Kintor Pharmaceutical Ltd. soared in Hong Kong after saying its pill was highly effective in reducing the risk of hospitalization or deaths related to Covid-19, raising the prospect of a first homegrown antiviral treatment.Shares were up 141% as of 11:06 a.m. local time after earlier surging as much as 229%, the biggest jump since the company’s Hong Kong listing in mid-2020. The stock was also the best performer on the the Hang Seng Composite Index, which slid 1.6%.The drug, proxalutamide, cut the risk of hospitalization or deaths by 50% to 100% as compared to a controlled group, depending on the days of treatment, Suzhou-based Kintor said in an exchange statement, citing data from its latest U.S. clinical trial. Effectiveness was better for high-risk groups, the firm added, reducing hospitalization and deaths by 100% among those aged 50 or above with obesity.Read more: China Drugmaker’s 580% Surge Has Analysts Wanting MoreIf results hold, the drug would become the first Covid-19 antiviral oral drug developed by a Chinese firm, adding to antiviral treatments available from Pfizer Inc. and Merck & Co Inc. China approved Pfizer’s Paxlovid in February and has been using it to treat patients in the current outbreak as daily cases exceed 20,000 this week amid omicron’s spread in Shanghai.Kintor shares surged more than 600% between January and August last year, as traders bet on a potential commercial windfall of an oral Covid treatmen. Shares then plunged in the fourth quarter due to failed clinical tests and the launch of Covid pills by overseas competitors.The company’s trading volume in the first hour of Wednesday trading is more than 400% of its 3-month full-day average. Its current price is 22% higher than the average target of analysts tracked by Bloomberg.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":108,"commentSize":12,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}